Abstract
Managing pregnancy in patients with end-stage renal disease (ESRD) on maintenance hemodialysis presents significant clinical challenges, particularly in determining the optimal "dry weight" (DW). This report details two successful pregnancies where plasma α-human atrial natriuretic peptide (α-hANP) was utilized as a biochemical marker for fluid management. Both patients, aged 30 and 31, were maintained on recombinant erythropoietin (rEPO) to sustain hematocrit levels above 30%. By monitoring α-hANP levels and adjusting dialysis targets accordingly, both pregnancies reached 34 weeks, resulting in the delivery of healthy infants via Caesarean section.
Introduction
Pregnancy in dialysis patients is historically rare and associated with high risks of maternal hypertension, severe anemia, and fetal growth restriction. A primary hurdle is the accurate determination of dry weight—the patient's weight at the end of a dialysis session when excess fluid is removed. Normal pregnancy-related weight gain (fetus, placenta, amniotic fluid) often masks pathological fluid retention. Over-aggressive fluid removal can lead to maternal hypotension and placental insufficiency, while under-removal risks heart failure and pulmonary edema. This study evaluates the utility of α-hANP as an objective physiological guide for fluid management in these complex cases.
Clinical Cases and Methods
The study follows two patients at Kanazawa Medical University:
- Case 1: A 30-year-old woman on dialysis for 6 years.
- Case 2: A 31-year-old woman who returned to dialysis after a failed renal transplant.
Both patients received rEPO to maintain stable hematocrit levels, a critical factor for fetal oxygenation. The innovative aspect of their care was the longitudinal measurement of plasma α-hANP. This peptide is secreted by the cardiac atria in response to volume-induced stretch, making it a direct proxy for cardiac preload. The clinical team aimed for an α-hANP target range of 50–70 pg/ml to guide fluid removal. Dialysis frequency was increased to up to four times per week, and tocolytic therapy was administered to prevent premature labor.
Historical Context and Data
To contextualize these outcomes, the authors reviewed 34 previously reported cases of pregnancy on dialysis in Japan up to 1991. This historical data highlights the variability in gestational age at delivery and birth weights, underscoring the high-risk nature of these pregnancies.
Key Insights: α-hANP as a "Volume Compass"
The use of α-hANP provided a more objective metric than traditional physical examinations or chest X-rays. In Case 2, monitoring revealed a significant spike in α-hANP levels (exceeding 100 pg/ml), which served as an early warning sign of fluid overload (polyhydramnios) before the onset of severe clinical symptoms. This allowed for preemptive adjustments to the dry weight target.
Furthermore, the team observed that maintaining α-hANP at levels slightly lower than those typically seen in healthy pregnant women helped mitigate the hypertensive complications often seen in dialysis-dependent pregnancies. The synergy between precise fluid management and rEPO therapy was vital; rEPO maintained stable hematocrit levels without the need for frequent blood transfusions.
Results and Outcomes
Both patients successfully delivered via Caesarean section at 34 weeks:
- Case 1: Male infant, 1,613g, Apgar score 9.
- Case 2: Male infant, 1,713g, Apgar score 8.
Despite low birth weights due to prematurity, both infants were healthy and survived. Throughout the pregnancies, Blood Urea Nitrogen (BUN) was kept below 70 mg/dl and Creatinine (Cr) remained around 6–7 mg/dl, meeting recommended thresholds to minimize fetal toxicity.
Conclusion
While limited by a small sample size, these cases demonstrate that α-hANP monitoring is a valuable tool for managing the "moving target" of dry weight in pregnant dialysis patients. By providing a physiological marker for cardiac preload, α-hANP allows for safer, more precise fluid management, reducing the risks of both volume overload and placental hypoperfusion. This approach, combined with modern anemia management via rEPO, significantly improves the prospects for successful pregnancy outcomes in ESRD patients.
Summary updated